Results 1 to 10 of about 315,339 (432)
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
Research and Practice in Thrombosis and Haemostasis, 2022 Background Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded)
Emmanuel J Favaloro, Leonardo Pasalic
exaly +4 more sources
Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications
Cells, 2022 Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent) venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a century, and, nowadays, physicians possess a broad panel of multiple ...
Marco Heestermans +4 more
doaj +2 more sources
Anticoagulants and Osteoporosis [PDF]
International Journal of Molecular Sciences, 2019 Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong
S. Signorelli +5 more
semanticscholar +4 more sources
Journal of Thrombosis and Haemostasis, 2018 Essentials Direct oral anticoagulants (DOACs) do not require laboratory monitoring currently. DOAC specific measurements were performed at trough in patients with atrial fibrillation.
Vittorio Pengo
exaly +2 more sources
A Study of Using Anticoagulants in a Tertiary Care Hospital in Bangalore: A Prospective Study [PDF]
Journal of Health Sciences and Surveillance System, 2021 Background: drug utilization studies are necessary to evaluate the rational use and associated risks of anticoagulants. This study aimed to identify drug utilization pattern and possible drug interactions with the use of anticoagulants in a tertiary care
Shahrzad Raouf +3 more
doaj +1 more source
Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2022 A post-COVID patient with a high D-dimer Value (>5000 IU) was posted for total knee replacement. She was on multiple anticoagulants including the novel oral anticoagulants that started to reduce thrombotic risk.
Balasubramaniam Gayathri +3 more
doaj +1 more source
Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs
Российский кардиологический журнал, 2021 The use of direct oral anticoagulants minimized the risks associated with vitamin K antagonist (warfarin) therapy. Currently, direct oral anticoagulants have priority over warfarin for the prevention of thromboembolic events in patients with atrial ...
B. A. Tatarsky, N. V. Kazyonnova
doaj +1 more source
IMPACT OF NON-VITAMIN K ORAL ANTI-COAGULANTS ON WARFARIN UTILISATION AND NHS BUDGET IN UK
Global Journal of Public Health Medicine, 2022 Introduction: Vitamin K anticoagulants were the mainstay prophylaxis of stroke in patients with atrial fibrillation and thromboembolic diseases. Non-vitamin K oral anticoagulants were approved for use in UK.
Mohammed Aladul +2 more
doaj +1 more source
Anticoagulants for people hospitalised with COVID-19.
Cochrane Database of Systematic Reviews, 2022 BACKGROUND The primary manifestation of coronavirus disease 2019 (COVID-19) is respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and thromboembolic events, such as pulmonary embolism, deep vein thrombosis, or ...
R. Flumignan +9 more
semanticscholar +1 more source
Reviews in Cardiovascular Medicine, 2022 After reading with great interest the article entitled: “Non-vitamin K antagonist oral anticoagulants (NOACs) do not increase the risk of hepatic impairment in patients with non-valvular atrial fibrillation: insights from multi-source medical data ...
Aleksandr Urakov +4 more
doaj +1 more source